Average cost of drugs for extensively drug-resistant tuberculosis in Sudan
Sudan: Average cost of drugs for extensively drug-resistant tuberculosis was 1,962 constant 2022 US$ in 2023. ◆ Volatile
Latest (2023)
1,962 constant 2022 US$
Change on year
up 96.2%
World rank
26th
of 56 countries
All-time high
9,330 constant 2022 US$
in 2018
All-time low
830 constant 2022 US$
in 2019
Years of data
6
2018–2023
Average cost of drugs for extensively drug-resistant tuberculosis in Sudan, 2018–2023
Source: WHO (2025) – with minor processing by Our World in Data. Measured in constant 2022 US$.
Analysis
Sudan recorded 1,962 constant 2022 US$ for average cost of drugs for extensively drug-resistant tuberculosis in 2023.
That represents a change of up 96.2% on the previous year and down 79.0% over ten years.
Sudan ranks 26th of 56 countries on this measure, in the middle of the range.
Average cost of drugs for extensively drug-resistant tuberculosis in Sudan, year by year
| Year | constant 2022 US$ | Change |
|---|---|---|
| 2018 | 9,330 constant 2022 US$ | — |
| 2019 | 830 constant 2022 US$ | -91.1% |
| 2020 | 1,862 constant 2022 US$ | +124.3% |
| 2021 | 1,862 constant 2022 US$ | +0.0% |
| 2022 | 1,000 constant 2022 US$ | -46.3% |
| 2023 | 1,962 constant 2022 US$ | +96.2% |
Sudan compared with similar countries
- Sudan's 1,962 constant 2022 US$ is above the median for low income countries, which is 1,709 constant 2022 US$, 1.1× the median. (9 countries reporting)
- Sudan's 1,962 constant 2022 US$ is above the median for Sub-Saharan Africa, which is 1,500 constant 2022 US$, 1.3× the median. (20 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 5,080 constant 2022 US$ | 830 constant 2022 US$ | 9,330 constant 2022 US$ | 2 |
| 2020s | 1,672 constant 2022 US$ | 1,000 constant 2022 US$ | 1,962 constant 2022 US$ | 4 |
Countries ranked near Sudan
More reference data data for Sudan
- Emission Totals - Indirect emissions (N2O) - Manure applied to Soils 0.5846 (2019)
- Emission Totals - Indirect emissions (N2O) - Manure left on Pasture 17.81 (2019)
- Emission Totals - Indirect emissions (N2O) - IPCC Agriculture 19.69 (2019)
- Emission Totals - Indirect emissions (N2O) - Crop Residues 0.4356 (2019)
- Emission Totals - Indirect emissions (N2O) - Agricultural Soils 19.69 (2019)
- Emission Totals - Emissions (N2O) - Manure applied to Soils 1.96 (2019)
- Emission Totals - Emissions (N2O) - Manure Management 0.8148 (2019)
- Emission Totals - Emissions (N2O) - Manure left on Pasture 80.68 (2019)
- Emission Totals - Emissions (N2O) - IPCC Agriculture 93.88 (2019)
- Emission Totals - Emissions (N2O) - Crop Residues 2.37 (2019)
Frequently asked questions
- What is average cost of drugs for extensively drug-resistant tuberculosis in Sudan?
- Average cost of drugs for extensively drug-resistant tuberculosis in Sudan was 1,962 constant 2022 US$ in 2023, according to WHO (2025) – with minor processing by Our World in Data.
- What is the highest average cost of drugs for extensively drug-resistant tuberculosis recorded in Sudan?
- The highest recorded value was 9,330 constant 2022 US$ in 2018.
- What is the lowest average cost of drugs for extensively drug-resistant tuberculosis recorded in Sudan?
- The lowest recorded value was 830 constant 2022 US$ in 2019.
- How does Sudan rank for average cost of drugs for extensively drug-resistant tuberculosis?
- Sudan ranks 26th out of 56 countries with data for 2023.
- Is average cost of drugs for extensively drug-resistant tuberculosis rising or falling in Sudan?
- Over the last ten years it is down 79.0%. The long-run trend across the full record is volatile.
- Where does this Sudan data come from?
- The figures come from WHO (2025) – with minor processing by Our World in Data, published as part of Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 6 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.